Drug Modeling | Market Size, Share & Growth Report 2025-2033
The Drug Modeling Market Report is Segmented by Product Type (In-vitro Drug Modeling, In-silico Drug Modeling, In-vivo Drug Modeling, Ex-vivo Drug Modeling, and Microfluidic Drug Modeling), Application (Drug Discovery, Drug Development, Drug Repurposing, Personalized Medicine, and Toxicity Prediction), Distribution Channel (Pharmaceutical Companies, Contract Research Organizations, Academic Research Institutes, Biotechnology Companies, and Others), Modeling Technique (Quantitative Structure-Activity Relationship (QSAR), Molecular Docking, Pharmacophore Modeling, Molecular Dynamics Simulation, and Physiologically-Based Pharmacokinetic (PBPK) Modeling).
Drug Modeling Market
Market Analysis
How the market stands today, and what is shaping it
The global drug modeling market was estimated at approximately USD 12.52 billion in 2025 and is projected to reach around USD 28.03 billion by 2033, representing a CAGR of approximately 10.60% during 2025–2033, based on Core Market Research estimates. The market covers in-silico, in-vitro, in-vivo, ex-vivo and microfluidic modelling, applying QSAR, molecular docking, pharmacophore modelling, molecular dynamics and physiologically based pharmacokinetic techniques across discovery, development, repurposing, personalised medicine and toxicity prediction. Growth is supported by regulatory acceptance, with 74 of 243 novel drugs approved by the FDA between 2019 and 2023 involving PBPK modelling, by modelling substituting for experiments, by reform reducing reliance on animal studies, and by contract organisations extending access to smaller sponsors. Expansion is constrained by regulatory confidence concentrated in one technique, by scarce computational pharmacology expertise, and by in-vivo modelling contracting while other categories grow. Published estimates range from about USD 4.07 billion to USD 9.47 billion for 2025 depending on scope, and North America leads on documented commercial concentration.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Regulators now accept simulation as evidence rather than as supporting colour, with 74 of 243 novel drugs approved by the FDA between 2019 and 2023 involving physiologically based pharmacokinetic modelling, an inclusion rate of roughly 30%.
- Modelling substitutes for experiments that would otherwise cost time and money, and toxicity prediction is the clearest case, since a statistical relationship between structure and effect can replace a test rather than merely inform where to look next.
- Regulatory reform has loosened the assumption that animal studies are a required step, which redirects spending toward in-vitro, ex-vivo and microfluidic systems that model human tissue rather than a surrogate species.
- Modelling that supports a regulatory filing is funded as part of development cost rather than from discretionary research budget, which makes that portion of demand far more resilient to a sponsor tightening its spending.
- Suppliers continue to invest in the techniques with the clearest acceptance, and Certara enhanced its biosimulation portfolio with new physiologically based pharmacokinetic capabilities in June 2025 to support preclinical and clinical development.
Market Challenges
- The stored growth rate of 22.50% was recalculated to 10.60%. Published rates for this market and its components run from about 8.8% for drug modeling software to 14.5% for the narrower in-silico category, so the stored rate exceeded every available estimate.
- Published sizing varies widely by scope, from about USD 4.07 billion for in-silico drug discovery in 2025 to roughly USD 9.47 billion for drug modeling software. Comparing figures across sources requires checking whether laboratory model systems are counted.
- A model is only as good as its acceptance, and regulatory confidence is concentrated in physiologically based pharmacokinetic methods. Techniques without that standing compete on internal efficiency arguments that are harder to price.
- In-vivo modelling is a named product type facing structural decline as animal testing requirements loosen, so one of the five supplied categories is contracting while the others expand.
- Adoption depends on skilled users rather than on capital, and computational pharmacology expertise is scarce relative to demand, which limits how quickly a licensed platform converts into productive use.
Opportunities
- Organ-on-chip and microfluidic systems could take share from both cell culture and animal studies by offering perfused human tissue, which addresses the central objection to each of the alternatives they replace.
- Physiologically based pharmacokinetic modelling already represents the body as a system of compartments, so extending it to an individual's physiology is the most direct available route into personalised dosing.
- Drug repurposing suits computational screening particularly well, since searching an existing compound library against a new target is a search problem rather than a synthesis problem and requires no new chemistry.
- Wider regulatory acceptance beyond pharmacokinetics, into efficacy or safety modelling, would move more techniques from discretionary research spending into funded development cost, which is the transition that made PBPK commercially durable.
- Service-based delivery from lower-cost regions may extend modelling to sponsors that cannot justify licensing a platform, and in-silico work transfers far more readily than laboratory systems requiring physical facilities.
Trends and Insights
Key market trends shaping the industry landscape
Simulation Became Regulatory Evidence
High impactLong-termOf 243 novel drugs approved by the FDA between 2019 and 2023, 74 applications involved physiologically based pharmacokinetic modelling.
Insight: Once a technique appears in a submission it stops being an efficiency tool and becomes part of development cost, which is why PBPK is commercially more secure than methods with better science but less acceptance.
The Animal Model Is the Shrinking Segment
High impactLong-termIn-vivo modelling is a named product type in a market where regulatory reform has loosened the assumption that animal studies are required.
Insight: One of the five supplied categories is contracting while the rest expand, so a single blended growth rate for this market averages a declining business against four growing ones.
Scope Doubles the Estimate
Medium impactShort-termPublished 2025 sizing runs from about USD 4.07 billion for in-silico drug discovery to roughly USD 9.47 billion for drug modeling software.
Insight: Because the categories nest inside one another rather than competing, a reader comparing two published figures for this market is usually comparing two different definitions rather than two opinions.
Chips Replacing Both Alternatives
Medium impactMid-termMicrofluidic organ-on-chip systems offer perfused human tissue rather than static cell culture or a surrogate species.
Insight: This category competes against in-vitro and in-vivo modelling simultaneously, which is unusual, and it means its growth comes from displacing established spending rather than from new budget.
Skilled Users Gate Adoption
Medium impactMid-termModelling requires computational pharmacology expertise more than physical infrastructure.
Insight: A licence converts into productive work only when someone can run it competently, so supplier growth depends on training and service capacity as much as on the software itself.
Segment Analysis
Market segmentation by product type, application, distribution channel, modeling technique
In-silico Drug Modeling carries the largest share and the clearest growth case, and published sizing for the software category alone reached about USD 9.47 billion in 2025. In-vitro Drug Modeling covers cell-based and three-dimensional tissue systems used to test compounds before any animal work, and it has gained ground as those systems have become more predictive. In-vivo Drug Modeling is the animal component, and it is the one category under structural pressure, since regulatory reform has reduced the assumption that animal testing is a required step rather than one option among several. Ex-vivo Drug Modeling uses excised tissue and occupies a narrow but useful position between the two. Microfluidic Drug Modeling, commonly organ-on-chip systems, is the smallest and fastest growing, offering perfused human tissue as an alternative to both cell culture and animals.
Geography Analysis
Regional market analysis
North America
North America leads this market on documented commercial concentration rather than on a measured regional market size. The regulatory acceptance that underpins the most commercially secure technique originates here, with 74 of 243 novel drugs approved by the FDA between 2019 and 2023 involving physiologically based pharmacokinetic modelling. Four of the five most prominent participants in this market are United States companies, spanning biosimulation, molecular simulation, pharmacokinetic software and organ-on-chip systems, and Certara enhanced its PBPK capabilities from here in June 2025. No regional market size, revenue or growth figure was identified for any region in this market, and no company examined reports drug modeling revenue by region, so the ranking is a documented judgement rather than a measured one.
Europe
Europe combines a strong methodological research base with a regulatory environment that has pushed hardest on replacing animal studies, which shapes demand toward in-vitro, ex-vivo and microfluidic alternatives more than elsewhere. Dassault Systèmes SE anchors a European presence in molecular modelling software through its BIOVIA portfolio. The European Medicines Agency accepts modelling and simulation in submissions, though sponsors filing in both jurisdictions generally build to whichever expectation is more demanding rather than maintaining two approaches. Academic pharmacology and systems biology groups across the region contribute method development disproportionately to their commercial weight. No European market size, revenue or growth figure was identified.
Asia Pacific
No market size, revenue or growth figure specific to Asia Pacific was identified for this market. The structural position is that modelling software requires skilled users more than physical infrastructure, so adoption follows the depth of computational pharmacology training rather than capital availability. China, Japan, South Korea and India have all expanded domestic drug development, and contract research capacity in the region has grown to serve sponsors elsewhere, which pulls modelling work along with it. Lower staffing costs make service-based delivery of modelling competitive, and that applies to in-silico work far more readily than to laboratory model systems that need physical facilities.
Latin America
No market size, revenue or activity figure specific to Latin America was identified for this market. Drug development activity is concentrated in a small number of companies and academic centres, principally in Brazil, and much of the region's pharmaceutical industry focuses on generics and biosimilars where modelling plays a narrower role than in novel drug development. Bioequivalence work does use pharmacokinetic modelling, which provides a genuine if modest demand base. Software licensing rather than laboratory model systems accounts for most of what the region consumes.
Middle East & Africa
No market size, revenue or activity figure specific to the Middle East and Africa was identified for this market. Gulf states have funded pharmaceutical research institutes and computational infrastructure, creating demand for modelling software and training at modest scale. Across much of Africa, pharmaceutical activity centres on manufacturing and distribution rather than discovery, so demand for discovery-stage modelling is limited. Where regulatory science capacity is being developed, pharmacokinetic modelling for bioequivalence assessment is the most immediately applicable technique. The region contributes a small share of value.
Competitive Landscape
Key players and market positioning analysis
Competition here divides between companies selling simulation software, companies selling the laboratory systems that physical modelling requires, and service organisations that run either on a client's behalf. Certara, Inc. holds the strongest position in biosimulation, and its advantage rests on regulatory familiarity rather than on computational novelty, since physiologically based pharmacokinetic modelling is the technique regulators have most clearly accepted; it enhanced that portfolio with new PBPK capabilities in June 2025. Schrödinger, Inc. competes from the physics end, with molecular dynamics and docking tools used in discovery where the question is how a molecule and its target behave rather than how a drug distributes through a body. Dassault Systèmes SE participates through its BIOVIA portfolio, selling molecular modelling within a broader engineering software franchise, which gives it enterprise relationships that specialist vendors lack. Simulations Plus, Inc. competes directly with Certara in pharmacokinetic and structure-activity modelling, and its focus on that narrower field is its differentiator rather than a limitation. Emulate, Inc. represents the physical end of this market with organ-on-chip systems, competing against both cell culture and animal studies at once. The factors that decide outcomes are regulatory acceptance of the technique a supplier sells, validation data behind the models, the availability of users trained to operate them, and whether a vendor can deliver as a service to sponsors unwilling to build capability internally.
Major Players
Leading companies in the market
Industry Developments
4 recorded developments
Certara enhanced its biosimulation portfolio with new physiologically based pharmacokinetic modelling capabilities in June 2025, aimed at accelerating preclinical and clinical development. Investment continued to concentrate on the technique with the clearest regulatory acceptance.
Published estimates for the narrower in-silico drug discovery category clustered between about USD 4.07 billion and USD 5.27 billion for 2025, with growth rates from 11.25% to 14.5%. The gap against broader definitions reflects whether laboratory model systems are included.
Published sizing placed the drug modeling software category at about USD 8.70 billion for 2024, rising to roughly USD 9.47 billion in 2025. Software alone therefore accounts for a substantial majority of this market even before laboratory model systems are counted.
Of 243 novel drugs approved by the FDA between 2019 and 2023, 74 applications involved physiologically based pharmacokinetic modelling, an inclusion rate of roughly 30%. Simulation had moved from a research convenience into a component of regulatory submissions.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Modeling Technique
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Certara, Inc.
9.2 Schrödinger, Inc.
9.3 Dassault Systèmes SE
9.4 Simulations Plus, Inc.
9.5 Emulate, Inc.
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2033
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Certara, Inc., Schrödinger, Inc., Dassault Systèmes SE, Simulations Plus, Inc. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.